source
- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.
- STAT+: Argenx to buy Forte Biosciences for $2.2BArgenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.